trending Market Intelligence /marketintelligence/en/news-insights/trending/fnxyfib8n4hiix0uudqfjw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

AMAG Pharmaceuticals, Sandoz settle anemia drug patent case

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


AMAG Pharmaceuticals, Sandoz settle anemia drug patent case

AMAG Pharmaceuticals Inc. and Novartis AG's Sandoz Inc. unit agreed to settle their patent dispute involving the AMAG's anemia drug Feraheme.

AMAG received a notification from the U.S. Food and Drug Administration when Sandoz filed a Paragraph IV abbreviated new drug application for its generic version of the drug in 2016. In the filing, the generic-drug company said the generic copy does not infringe the listed patents in the FDA's Orange Book, or that such patents are invalid or unenforceable.

If Sandoz wins the FDA's approval by a certain date, the Novartis unit may launch the generic copy July 15, 2021, or earlier under certain circumstances. Sandoz will also pay AMAG a royalty on the generic's sales until the last Feraheme patent listed in the Orange Book expires.

However, if the U.S. regulator rejects Sandoz's application, the company may launch the approved generic version July 15, 2022, for a one-year period.

AMAG believes the settlement allows the continued advancement of Feraheme in the U.S. iron market.